Cytotoxic Effects of Dibromoisatin Derivatives on Hela and HepG2 Cell Lines Using MTT Assay

Background and purpose: Tumors are one of the most important threats to human life and improving the drugs used in their treatment is always necessary.  Isatin is found in many plants and also synthesized through different methods.  Many studies have been done on Isatin ring, including the construct...

Full description

Bibliographic Details
Main Authors: Mohammad Shokrzadeh, Saied Emami, Melika Amirzadeh, Mona Modanloo
Format: Article
Language:English
Published: Mazandaran University of Medical Sciences 2017-08-01
Series:Journal of Mazandaran University of Medical Sciences
Subjects:
Online Access:http://jmums.mazums.ac.ir/article-1-8870-en.html
Description
Summary:Background and purpose: Tumors are one of the most important threats to human life and improving the drugs used in their treatment is always necessary.  Isatin is found in many plants and also synthesized through different methods.  Many studies have been done on Isatin ring, including the construction of Dibromoisatin derivatives that exhibit anti-cancer effects. The aim of this study was to determine the cytotoxic effects of Dibromoisatin derivatives on cervical and liver cancer cells. Materials and methods: In this study, 10 Dibromoisatin derivative made at concentrations of 1, 50, 100, 200, and 400 µg/mL were tested against cervical (HeLa) and liver cancer cell lines (HepG2). The cell viability was assessed by MTT assay and the IC50 value was calculated in PRISM software. Results: Comparing the cytotoxic effects of Dibromoisatin derivatives showed that the highest cytotoxic effects in both cell lines was detected in composition No. 9 with IC50 value of HepG2= 1.194 and IC50 value of HeLa= 0.025. Conclusion: These derivatives were more effective against liver cancer cells and some Dibromoisatin derivatives were found to have high toxicity against cancer cells, therefore, they could be of great benefit in improving the drugs used in chemotherapy.
ISSN:1735-9260
1735-9279